CoChat
Sign Up
Cited by 39

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Exosomes in cancer immunoediting and immunotherapy

Zhao, Yarong, Liu, Luotong, Sun, Rongze, Cui, Guilin, Guo, Shuyu, Han, Songren, Li, Ziwei, Bai, Tian, Teng, Lesheng·2022·Asian Journal of Pharmaceutical Sciences
DOI 10.1016/j.ajps.2021.12.001PMC PMC9091780
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajps.2021.12.001

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract Graphical abstract Exosomes mediate important cell communication in the process of tumor immunoediting. In the elimination phase, tumor-derived exosomes (TEs) activate the immune system, and immune cell-derived exosomes have a strong ability to inhibit tumors. The role of exosomes between the tumor and the immune system in the balance phase has not yet been studied. In the escape phase, TEs still have a significant role in the suppression of immune response cells, the activation of immunosuppressive cells and the promotion of the polarization of macrophages in the microenvironment. Different tumor immunotherapy strategies have been developed, such as cancer vaccines and various drug delivery vehicles. Although there are various obstacles to separation, purification and clinical application, as biologically derived nanovesicles, exosomes still have broad researched value and application prospects.
Graphical abstract Graphical abstract Exosomes mediate important cell communication in the process of tumor immunoediting. In the elimination phase, tumor-derived exosomes (TEs) activate the immune system, and immune cell-derived exosomes have a strong ability to inhibit tumors. The role of exosomes between the tumor and the immune system in the balance phase has not yet been studied. In the escape phase, TEs still have a significant role in the suppression of immune response cells, the activation of immunosuppressive cells and the promotion of the polarization of macrophages in the microenvironment. Different tumor immunotherapy strategies have been developed, such as cancer vaccines and various drug delivery vehicles. Although there are various obstacles to separation, purification and clinical application, as biologically derived nanovesicles, exosomes still have broad researched value and application prospects.CC BY-NC-ND · PubMed Central
Fig. 1 The secretion mechanism and composition of exosomes. Exosomes originate from endosomes formed by cell membrane invagination. Early endosomes gradually develop into late endosomes containing multiple vesicles after material sorting and transportation. The small vesicles finally released to the outside through membrane fusion are exosomes. Small extracellular vesicles formed by plasma membrane budding may also be considered exosomes. Exosomes have a phospholipid bilayer and rich in tetraspanins, annexins, integrins, chaperones, lipids and nucleic acids.
Fig. 1 The secretion mechanism and composition of exosomes. Exosomes originate from endosomes formed by cell membrane invagination. Early endosomes gradually develop into late endosomes containing multiple vesicles after material sorting and transportation. The small vesicles finally released to the outside through membrane fusion are exosomes. Small extracellular vesicles formed by plasma membrane budding may also be considered exosomes. Exosomes have a phospholipid bilayer and rich in tetraspanins, annexins, integrins, chaperones, lipids and nucleic acids.CC BY-NC-ND · PubMed Central
Fig. 2 The framework is used to explore relevant literature on exosomes and tumor immunity. Step 1: input keywords, search all in PubMed, and count the frequency of keywords. Our keywords are “exosome/small extracellular vesicle”, “tumor/cancer” and “tumor microenvironment”. After screened, 726 articles were obtained. Based on the biomedical network and MORM model to expand and search for related entities, finding relevant entities such as “macrophages”, “dendritic cells”, “mast cells”, “natural killer cells”, “myeloid-derived suppressor cells” and “cytotoxicity T lymphocytes”; Step 2: Fine-tune the named entity recognition model to search for the most relevant documents describing the relationship between keywords and entities. In the end, we obtained 358 target documents.
Fig. 2 The framework is used to explore relevant literature on exosomes and tumor immunity. Step 1: input keywords, search all in PubMed, and count the frequency of keywords. Our keywords are “exosome/small extracellular vesicle”, “tumor/cancer” and “tumor microenvironment”. After screened, 726 articles were obtained. Based on the biomedical network and MORM model to expand and search for related entities, finding relevant entities such as “macrophages”, “dendritic cells”, “mast cells”, “natural killer cells”, “myeloid-derived suppressor cells” and “cytotoxicity T lymphocytes”; Step 2: Fine-tune the named entity recognition model to search for the most relevant documents describing the relationship between keywords and entities. In the end, we obtained 358 target documents.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 184

  1. Vlassov, 2012, Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials, Biochim Biophys Acta, 1820, 940, 10.1016/j.bbagen.2012.03.017 · DOI
  2. Li, 2019, Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma, Cell Mol Life Sci, 76, 4203, 10.1007/s00018-019-03215-0 · DOI
  3. Bang, 2012, Exosomes: new players in cell-cell communication, Int J Biochem Cell Biol, 44, 2060, 10.1016/j.biocel.2012.08.007 · DOI
  4. Bu, 2019, Exosomes: isolation, analysis, and applications in cancer detection and therapy, Chembiochem, 20, 451, 10.1002/cbic.201800470 · DOI
  5. Beuzelin, 2018, Exosomes and mirna-loaded biomimetic nanovehicles, a focus on their potentials preventing type-2 diabetes linked to metabolic syndrome, Front Immunol, 9, 2711, 10.3389/fimmu.2018.02711 · DOI
  6. Xie, 2019, Extracellular vesicles in cancer immune microenvironment and cancer immunotherapy, Adv Sci, 6, 10.1002/advs.201901779 · DOI
  7. Dunn, 2002, Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, 3, 991, 10.1038/ni1102-991 · DOI · Paper page
  8. Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486 · DOI · Paper page
  9. Mittal, 2014, New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape, Curr Opin Immunol, 27, 16, 10.1016/j.coi.2014.01.004 · DOI · Paper page
  10. Nakamura, 2020, Cancer immunoediting and immune dysregulation in multiple myeloma, Blood, 136, 2731, 10.1182/blood.2020006540 · DOI
  11. Anichini, 2020, Immune escape mechanisms in non-small cell lung cancer, Cancers, 12, 3605, 10.3390/cancers12123605 · DOI
  12. O'donnell, 2019, Cancer immunoediting and resistance to T cell-based immunotherapy, Nat Rev Clin Oncol, 16, 151, 10.1038/s41571-018-0142-8 · DOI
  13. Ding, 2021, A holistic review of the state-of-the-art microfluidics for exosome separation: an overview of the current status, existing obstacles, and future outlook, Small, 17, 10.1002/smll.202007174 · DOI
  14. Thery, 2018, Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines, J Extracell Vesicles, 7, 10.1080/20013078.2018.1535750 · DOI · Paper page
  15. Mathivanan, 2010, Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature, Mol Cell Proteomics, 9, 197, 10.1074/mcp.M900152-MCP200 · DOI
  16. Lai, 2010, Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury, Stem Cell Res, 4, 214, 10.1016/j.scr.2009.12.003 · DOI · Paper page
  17. Mittelbrunn, 2011, Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells, Nat Commun, 2, 282, 10.1038/ncomms1285 · DOI
  18. Webber, 2010, Cancer exosomes trigger fibroblast to myofibroblast differentiation, Cancer Res, 70, 9621, 10.1158/0008-5472.CAN-10-1722 · DOI
  19. Shen, 2011, Protein targeting to exosomes/microvesicles by plasma membrane anchors, J Biol Chem, 286, 14383, 10.1074/jbc.M110.208660 · DOI
  20. Tetta, 2013, Extracellular vesicles as an emerging mechanism of cell-to-cell communication, Endocrine, 44, 11, 10.1007/s12020-012-9839-0 · DOI
  21. Seo, 2019, Stem cell-derived extracellular vesicles as immunomodulatory therapeutics, Stem Cells Int, 2019, 10.1155/2019/5126156 · DOI
  22. Yin, 2020, PPARalpha inhibition overcomes tumor-derived exosomal lipid-induced dendritic cell dysfunction, Cell Rep, 33, 10.1016/j.celrep.2020.108278 · DOI
  23. Spellicy, 2021, Tissue and stem cell sourced extracellular vesicle communications with microglia, Stem Cell Rev Rep, 17, 357, 10.1007/s12015-020-10011-y · DOI
  24. Ju, 2021, The role of exosome and the escrt pathway on enveloped virus infection, Int J Mol Sci, 22, 9060, 10.3390/ijms22169060 · DOI
  25. Huang, 2018, Exosomes function in tumor immune microenvironment, Adv Exp Med Biol, 1056, 109, 10.1007/978-3-319-74470-4_7 · DOI
  26. Xu, 2016, Macrophages transfer antigens to dendritic cells by releasing exosomes containing dead-cell-associated antigens partially through a ceramide-dependent pathway to enhance CD4(+) T-cell responses, Immunology, 149, 157, 10.1111/imm.12630 · DOI
  27. Wei, 2021, Rab31 marks and controls an ESCRT-independent exosome pathway, Cell Res, 31, 157, 10.1038/s41422-020-00409-1 · DOI
  28. SW, 2016, Exosomes as therapeutics: the implications of molecular composition and exosomal heterogeneity, J Control Release, 228, 179, 10.1016/j.jconrel.2016.02.037 · DOI
  29. Thery, 2001, Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles, J Immunol, 166, 7309, 10.4049/jimmunol.166.12.7309 · DOI
  30. Hoshino, 2015, Tumour exosome integrins determine organotropic metastasis, Nature, 527, 329, 10.1038/nature15756 · DOI · Paper page
  31. Li, 2019, Challenges and opportunities in exosome research-perspectives from biology, engineering, and cancer therapy, Apl Bioeng, 3, 10.1063/1.5087122 · DOI
  32. Thery, 2002, Exosomes: composition, biogenesis and function, Nat Rev Immunol, 2, 569, 10.1038/nri855 · DOI
  33. Jeppesen, 2019, Reassessment of exosome composition, Cell, 177, 428, 10.1016/j.cell.2019.02.029 · DOI · Paper page
  34. Donoso-Quezada, 2021, The role of lipids in exosome biology and intercellular communication: function, analytics, and applications, Traffic, 22, 204, 10.1111/tra.12803 · DOI
  35. Guescini, 2010, Astrocytes and glioblastoma cells release exosomes carrying mtDNA, J Neural Transm, 117, 1, 10.1007/s00702-009-0288-8 · DOI
  36. Mathivanan, 2010, Exosomes: extracellular organelles important in intercellular communication, J Proteomics, 73, 1907, 10.1016/j.jprot.2010.06.006 · DOI
  37. Valadi, 2007, Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat Cell Biol, 9, 654, 10.1038/ncb1596 · DOI · Paper page
  38. Lan, 2021, Serum exosomal lncRNA xist is a potential non-invasive biomarker to diagnose recurrence of triple-negative breast cancer, J Cell Mol Med, 25, 7602, 10.1111/jcmm.16009 · DOI
  39. Yang, 2021, Tumor-derived exosomal circRNA_102481 contributes to EGFR-TKIs resistance via the miR-30a-5p/ROR1 axis in non-small cell lung cancer, Aging-Us, 13, 13264, 10.18632/aging.203011 · DOI
  40. Zuo, 2020, Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice, Nat Commun, 11, 1790, 10.1038/s41467-020-15569-2 · DOI
  41. Lv, 2020, Nonmuscle myosin heavy chain IIA-mediated exosome release via regulation of the rho-associated kinase 1/myosin light chains/actin pathway, Front Pharmaco, 11
  42. Dou, 2020, Cancer-associated fibroblasts-derived exosomes suppress immune cell function in breast cancer via the miR-92/PD-L1 pathway, Front Immunol, 11, 2026, 10.3389/fimmu.2020.02026 · DOI
  43. Haraszti, 2016, High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources, J Extracell Vesicles, 5, 32570, 10.3402/jev.v5.32570 · DOI · Paper page
  44. Mathieu, 2021, Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9, Nat Commun, 12, 4389, 10.1038/s41467-021-24384-2 · DOI · Paper page
  45. Li, 2021, Exosomes derived from RM-1 cells promote the recruitment of MDSCs into tumor microenvironment by upregulating CXCR4 via TLR2/NF-kappa B pathway, J Oncol, 2021, 10.1155/2021/5584406 · DOI
  46. Li, 2019, Challenges and opportunities in exosome research-perspectives from biology, engineering, and cancer therapy, Apl Bioeng, 3, 10.1063/1.5087122 · DOI
  47. Kharaziha, 2012, Tumor cell-derived exosomes: a message in a bottle, Biochim Biophys Acta, 1826, 103
  48. Milane, 2015, Exosome mediated communication within the tumor microenvironment, J Control Release, 219, 278, 10.1016/j.jconrel.2015.06.029 · DOI
  49. Kim, 2020, Exosomes: cell-derived nanoplatforms for the delivery of cancer therapeutics, Int J Mol Sci, 22, 14, 10.3390/ijms22010014 · DOI
  50. Hoshino, 2015, Tumour exosome integrins determine organotropic metastasis, Nature, 527, 329, 10.1038/nature15756 · DOI · Paper page
  51. Rabinowits, 2009, Exosomal microrna: a diagnostic marker for lung cancer, Clin Lung Cancer, 10, 42, 10.3816/CLC.2009.n.006 · DOI
  52. Fan, 2019, Exosome-specific tumor diagnosis via biomedical analysis of exosome-containing microRNA biomarkers, Analyst, 144, 5856, 10.1039/C9AN00777F · DOI
  53. Wang, 2020, In situ multiplex detection of serum exosomal microRNAs using an all-in-one biosensor for breast cancer diagnosis, Analyst, 145, 3289, 10.1039/D0AN00393J · DOI
  54. Roman-Canal, 2019, EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer, Sci Rep-Uk, 9, 15057, 10.1038/s41598-019-51578-y · DOI
  55. Wolfers, 2001, Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming, Nat Med, 7, 297, 10.1038/85438 · DOI
  56. Zitvogel, 1998, Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes, Nat Med, 4, 594, 10.1038/nm0598-594 · DOI
  57. Matsumoto, 2020, Antitumor immunity by small extracellular vesicles collected from activated dendritic cells through effective induction of cellular and humoral immune responses, Biomaterials, 252, 10.1016/j.biomaterials.2020.120112 · DOI
  58. Lugini, 2012, Immune surveillance properties of human NK cell-derived exosomes, J Immunol, 189, 2833, 10.4049/jimmunol.1101988 · DOI
  59. Li, 2017, IL-12 stimulates CTLs to secrete exosomes capable of activating bystander CD8(+) T cells, Sci Rep, 7, 13365, 10.1038/s41598-017-14000-z · DOI
  60. Desai, 2021, Therapeutic applications of the cancer immunoediting hypothesis, Semin Cancer Biol
  61. Koebel, 2007, Adaptive immunity maintains occult cancer in an equilibrium state, Nature, 450, 903, 10.1038/nature06309 · DOI
  62. Mittal, 2014, New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape, Curr Opin Immunol, 27, 16, 10.1016/j.coi.2014.01.004 · DOI · Paper page
  63. Benito-Martin, 2015, The new deal a potentia role for secretec vesicles in innate immunity and tumor progression, Front Immunol, 6, 1
  64. Sinha, 2021, Trends in research on exosomes in cancer progression and anticancer therapy, Cancers (Basel), 13, 326, 10.3390/cancers13020326 · DOI
  65. Xie, 2019, Extracellular vesicles in cancer immune microenvironment and cancer immunotherapy, Adv Sci, 6, 10.1002/advs.201901779 · DOI
  66. Droste, 2020, Tumor-derived extracellular vesicles and the immune system-lessons from immune-competent mouse-tumor models, Front Immunol, 11
  67. Jafari, 2020, Hypoxic exosomes orchestrate tumorigenesis: molecular mechanisms and therapeutic implications, J Transl Med, 18, 474, 10.1186/s12967-020-02662-9 · DOI
  68. Bai, 2016, A method for exploring implicit concept relatedness in biomedical knowledge network, BMC Bioinformatics, 17, 265, 10.1186/s12859-016-1131-5 · DOI
  69. Bai, 2019, Berst: an engine and tool for exploring biomedical entities and relationships, Chinese J Electron, 28, 797, 10.1049/cje.2019.05.007 · DOI
  70. Zhu, 2020, A novel deep learning model using dosimetric and clinical information for grade 4 radiotherapy-induced lymphopenia prediction, Phys Med Biol, 65, 10.1088/1361-6560/ab63b6 · DOI
  71. Raposo, 1996, B lymphocytes secrete antigen-presenting vesicles, J Exp Med, 183, 1161, 10.1084/jem.183.3.1161 · DOI · Paper page
  72. Andre, 2004, Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells, J Immunol, 172, 2126, 10.4049/jimmunol.172.4.2126 · DOI · Paper page
  73. Leone, 2017, Surface LAMP-2 is an endocytic receptor that diverts antigen internalized by human dendritic cells into highly immunogenic exosomes, J Immunol, 199, 531, 10.4049/jimmunol.1601263 · DOI
  74. Besse, 2016, Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC, Oncoimmunology, 5, 10.1080/2162402X.2015.1071008 · DOI · Paper page
  75. Lindenbergh, 2018, Antigen presentation by extracellular vesicles from professional antigen-presenting cells, Annu Rev Immunol, 36, 435, 10.1146/annurev-immunol-041015-055700 · DOI
  76. Logozzi, 2009, High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients, PLoS ONE, 4, e5219, 10.1371/journal.pone.0005219 · DOI
  77. Dai, 2008, Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer, Mol Ther, 16, 782, 10.1038/mt.2008.1 · DOI
  78. Dubovsky, 2013, Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing, Blood, 122, 3308, 10.1182/blood-2013-05-504597 · DOI
  79. Hsu, 2003, Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides, J Immunother, 26, 440, 10.1097/00002371-200309000-00007 · DOI
  80. Leone, 2018, Dendritic cells and routing cargo into exosomes, Immunol Cell Biol, 96, 683, 10.1111/imcb.12170 · DOI
  81. Morelli, 2004, Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells, Blood, 104, 3257, 10.1182/blood-2004-03-0824 · DOI
  82. Reiners, 2014, Role of exosomes released by dendritic cells and/or by tumor targets: regulation of NK cell plasticity, Front Immunol, 5, 91
  83. Zech, 2012, Tumor-exosomes and leukocyte activation: an ambivalent crosstalk, Cell Commun Signal, 10, 37, 10.1186/1478-811X-10-37 · DOI
  84. Duray, 2010, Immune suppression in head and neck cancers: a review, Clin Dev Immunol, 2010
  85. Segura, 2007, CD8(+) dendritic cells use IFA-1 to capture mhc-peptide complexes from exosomes in vivo, J Immunol, 179, 1489, 10.4049/jimmunol.179.3.1489 · DOI
  86. Thery, 2002, Indirect activation of naïve CD4(+) T cells by dendritic cell-derived exosomes, Nat Immunol, 3, 1156, 10.1038/ni854 · DOI
  87. Segura, 2005, ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming, Blood, 106, 216, 10.1182/blood-2005-01-0220 · DOI
  88. Munich, 2012, Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands, Oncoimmunology, 1, 1074, 10.4161/onci.20897 · DOI
  89. Tavakoli, 2021, Cancer immunoediting: a game theoretical approach, In Silico Biol, 14, 1, 10.3233/ISB-200475 · DOI
  90. Hinata, 2020, Exosomes of Epstein-Barr virus-associated gastric carcinoma suppress dendritic cell maturation, Microorganisms, 8, 1776, 10.3390/microorganisms8111776 · DOI
  91. Ning, 2018, Tumor exosomes block dendritic cells maturation to decrease the T cell immune response, Immunol Lett, 199, 36, 10.1016/j.imlet.2018.05.002 · DOI
  92. Yu, 2020, EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells, Oncogene, 39, 2643, 10.1038/s41388-020-1182-y · DOI
  93. Ding, 2015, Pancreatic cancer-derived exosomes transfer mirnas to dendritic cells and inhibit RFXAP expression via miR-212-3p, Oncotarget, 6, 29877, 10.18632/oncotarget.4924 · DOI
  94. Vulpis, 2019, Cancer exosomes as conveyors of stress-induced molecules: new players in the modulation of NK cell response, Int J Mol Sci, 20, 611, 10.3390/ijms20030611 · DOI
  95. Briand, 2020, Radiotherapy-induced overexpression of exosomal miRNA-378a-3p in cancer cells limits natural killer cells cytotoxicity, Epigenomics, 12, 397, 10.2217/epi-2019-0193 · DOI
  96. Liu, 2006, Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function, J Immunol, 176, 1375, 10.4049/jimmunol.176.3.1375 · DOI
  97. Schroeder, 2020, Circulating exosomes inhibit b cell proliferation and activity, Cancers, 12, 2110, 10.3390/cancers12082110 · DOI
  98. Iorgulescu, 2016, The limited capacity of malignant glioma-derived exosomes to suppress peripheral immune effectors, J Neuroimmunol, 290, 103, 10.1016/j.jneuroim.2015.11.025 · DOI
  99. Sharma, 2020, Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells, Sci Rep, 10, 92, 10.1038/s41598-019-56542-4 · DOI
  100. Clayton, 2007, Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2, Cancer Res, 67, 7458, 10.1158/0008-5472.CAN-06-3456 · DOI
  101. Othman, 2019, Cancer-derived exosomes as effectors of key inflammation-related players, Front Immunol, 10, 2103, 10.3389/fimmu.2019.02103 · DOI
  102. Zhou, 2014, Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203, Cell Immunol, 292, 65, 10.1016/j.cellimm.2014.09.004 · DOI
  103. Berchem, 2016, Hypoxic tumor-derived microvesicles negatively regulate nk cell function by a mechanism involving TGF-beta and miR23a transfer, Oncoimmunology, 5, 10.1080/2162402X.2015.1062968 · DOI
  104. Ye, 2014, Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma, Oncotarget, 5, 5439, 10.18632/oncotarget.2118 · DOI
  105. Shen, 2020, Recent progress in tumor photodynamic immunotherapy, Chinese Chem Lett, 31, 1709, 10.1016/j.cclet.2020.02.007 · DOI
  106. Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 · DOI · Paper page
  107. Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating t cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci USA, 107, 4275, 10.1073/pnas.0915174107 · DOI · Paper page
  108. Gao, 2018, Expression profiles and clinical value of plasma exosomal TIM-3 and Galectin-9 in non-small cell lung cancer, Biochem Bioph Res Co, 498, 409, 10.1016/j.bbrc.2018.02.114 · DOI
  109. Chen, 2018, Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response, Nature, 560, 382, 10.1038/s41586-018-0392-8 · DOI · Paper page
  110. Xie, 2019, The role of exosomal PD-L1 in tumor progression and immunotherapy, Mol Cancer, 18, 146, 10.1186/s12943-019-1074-3 · DOI
  111. Whiteside, 2013, Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes), Biochem Soc Trans, 41, 245, 10.1042/BST20120265 · DOI
  112. Clayton, 2008, Human tumor-derived exosomes down-modulate NKG2d expression, J Immunol, 180, 7249, 10.4049/jimmunol.180.11.7249 · DOI
  113. Lundholm, 2014, Prostate tumor-derived exosomes down-regulate NKG2d expression on natural killer cells and CD8+ T cells: mechanism of immune evasion, PLoS ONE, 9, 10.1371/journal.pone.0108925 · DOI
  114. Chalmin, 2010, Membrane-associated HSP72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells, J Clin Invest, 120, 457
  115. Xiang, 2009, Induction of myeloid-derived suppressor cells by tumor exosomes, Int J Cancer, 124, 2621, 10.1002/ijc.24249 · DOI
  116. Gobbo, 2016, Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer, J Natl Cancer Inst, 108, djv330, 10.1093/jnci/djv330 · DOI
  117. Muller, 2016, Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets, Sci Rep, 6, 20254, 10.1038/srep20254 · DOI
  118. Muller, 2017, Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms, Oncoimmunology, 6, e1261243, 10.1080/2162402X.2016.1261243 · DOI
  119. Szajnik, 2010, Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg), PLoS ONE, 5, e11469, 10.1371/journal.pone.0011469 · DOI
  120. Ye, 2018, Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion, J Immunother Cancer, 6, 145, 10.1186/s40425-018-0451-6 · DOI
  121. Baig, 2020, Tumor-derived exosomes in the regulation of macrophage polarization, Inflamm Res, 69, 435, 10.1007/s00011-020-01318-0 · DOI
  122. Sica, 2012, Macrophage plasticity and polarization: in vivo veritas, J Clin Invest, 122, 787, 10.1172/JCI59643 · DOI · Paper page
  123. Kumar, 2019, Prognostic significance of tumor-associated macrophage content in head and neck squamous cell carcinoma: a meta-analysis, Front Oncol, 9, 656, 10.3389/fonc.2019.00656 · DOI
  124. Lu, 2019, Cy5.5-MSA-G250 nanoparticles (CMGNPs) induce M1 polarity of RAW264. 7 macrophage cells via TLR4-dependent manner, Chinese Chem Lett, 30, 1320, 10.1016/j.cclet.2019.03.001 · DOI
  125. Kanlikilicer, 2018, Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer, EBioMedicine, 38, 100, 10.1016/j.ebiom.2018.11.004 · DOI
  126. Cheng, 2017, Exosomes from melatonin treated hepatocellularcarcinoma cells alter the immunosupression status through STAT3 pathway in macrophages, Int J Biol Sci, 13, 723, 10.7150/ijbs.19642 · DOI
  127. Zeng, 2020, Non-covalent glycosylated gold nanoparticles/peptides nanovaccine as potential cancer vaccines, Chinese Chem Lett, 31, 1162, 10.1016/j.cclet.2019.10.015 · DOI
  128. Taieb, 2005, Dendritic cell-derived exosomes as cell-free peptide-based vaccines, Crit Rev Immunol, 25, 215, 10.1615/CritRevImmunol.v25.i3.30 · DOI
  129. Bu, 2015, Exosomes from dendritic cells loaded with chaperone-rich cell lysates elicit a potent T cell immune response against intracranial glioma in mice, J Mol Neurosci, 56, 631, 10.1007/s12031-015-0506-9 · DOI
  130. Morse, 2005, A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer, J Transl Med, 3, 9, 10.1186/1479-5876-3-9 · DOI
  131. Cheng, 2017, Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node, Mol Ther, 25, 1665, 10.1016/j.ymthe.2017.02.007 · DOI
  132. Zhang, 2019, Exosomes in cancer development, metastasis, and immunity, Biochim Biophys Acta Rev Cancer, 1871, 455, 10.1016/j.bbcan.2019.04.004 · DOI · Paper page
  133. Yang, 2007, Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells, J Cancer Res Clin Oncol, 133, 389, 10.1007/s00432-006-0184-7 · DOI
  134. Gu, 2015, Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice, Int J Cancer, 136, 74, 10.1002/ijc.29100 · DOI
  135. Hao, 2006, Dendritic cell-derived exosomes stimulate stronger CD8(+) CTL responses and antitumor immunity than tumor cell-derived exosomes, Cell Mol Immunol, 3, 205
  136. Chinnappan, 2020, Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs, Cancer Lett, 486, 18, 10.1016/j.canlet.2020.05.004 · DOI
  137. Wang, 2020, Exosomes as actively targeted nanocarriers for cancer therapy, Int J Nanomed, 15, 4257, 10.2147/IJN.S239548 · DOI
  138. Liu, 2021, Therapeutic applications of functional nanomaterials for prostatitis, Front Pharmacol, 12
  139. Koh, 2017, Exosome-sirpalpha, a CD47 blockade increases cancer cell phagocytosis, Biomaterials, 121, 121, 10.1016/j.biomaterials.2017.01.004 · DOI
  140. Syn, 2017, Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges, Trends Biotechnol, 35, 665, 10.1016/j.tibtech.2017.03.004 · DOI
  141. Li, 2017, Nano carriers for drug transport across the blood-brain barrier, J Drug Target, 25, 17, 10.1080/1061186X.2016.1184272 · DOI
  142. EL Andaloussi, 2013, Exosomes for targeted sirna delivery across biological barriers, Adv Drug Deliver Rev, 65, 391, 10.1016/j.addr.2012.08.008 · DOI
  143. Jia, 2018, NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo, Biomaterials, 178, 302, 10.1016/j.biomaterials.2018.06.029 · DOI · Paper page
  144. Lu, 2017, Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models, J Hepatol, 67, 739, 10.1016/j.jhep.2017.05.019 · DOI · Paper page
  145. Li, 2013, Exosomes derived from Rab27a-overexpressing tumor cells elicit efficient induction of antitumor immunity, Mol Med Rep, 8, 1876, 10.3892/mmr.2013.1738 · DOI
  146. Lv, 2012, Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro, J Biol Chem, 287, 15874, 10.1074/jbc.M112.340588 · DOI · Paper page
  147. Ko, 2015, Adipose-derived mesenchymal stem cell exosomes suppress hepatocellular carcinoma growth in a rat model: apparent diffusion coefficient, natural killer T-cell responses, and histopathological features, Stem Cells Int, 2015, 10.1155/2015/853506 · DOI · Paper page
  148. Liu, 2019, Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance, Biomaterials, 223, 10.1016/j.biomaterials.2019.119475 · DOI
  149. Feng, 2021, Folic acid-modified exosome-PH20 enhances the efficiency of therapy via modulation of the tumor microenvironment and directly inhibits tumor cell metastasis, Bioact Mater, 6, 963
  150. Morishita, 2016, Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA, Biomaterials, 111, 55, 10.1016/j.biomaterials.2016.09.031 · DOI
  151. Dai, 2006, Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells, J Mol Med, 84, 1067, 10.1007/s00109-006-0102-0 · DOI
  152. Zhou, 2021, Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment, Biomaterials, 268, 10.1016/j.biomaterials.2020.120546 · DOI · Paper page
  153. Zhang, 2010, Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma, Int J Oncol, 36, 133, 10.3892/ijo.2015.2993 · DOI · Paper page
  154. Guo, 2008, Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid, J Int Med Res, 36, 1342, 10.1177/147323000803600623 · DOI
  155. Zhang, 2018, Genetically engineered liposome-like nanovesicles as active targeted transport platform, Adv Mater, 30, 10.1002/adma.201705350 · DOI
  156. Rossowska, 2019, Antitumor potential of extracellular vesicles released by genetically modified murine colon carcinoma cells with overexpression of interleukin-12 and shRNA for TGF-beta 1, Front Immunol, 10, 211, 10.3389/fimmu.2019.00211 · DOI
  157. Morishita, 2017, Enhanced class I tumor antigen presentation via cytosolic delivery of exosomal cargos by tumor-cell-derived exosomes displaying a pH-sensitive fusogenic peptide, Mol Pharm, 14, 4079, 10.1021/acs.molpharmaceut.7b00760 · DOI
  158. Lee, 2011, Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects, Exp Mol Med, 43, 281, 10.3858/emm.2011.43.5.029 · DOI
  159. Shi, 2020, Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy, Mol Ther, 28, 536, 10.1016/j.ymthe.2019.11.020 · DOI
  160. Xie, 2010, Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8 + CTL responses and antitumor immunity, Cancer Biotherapy Radio, 25, 21
  161. Xu, 2019, CD8(+) T cells stimulated by exosomes derived from renca cells mediate specific immune responses through the Fasl/Fas signaling pathway and, combined with GM-CSF and IL-12, enhance the anti-renal cortical adenocarcinoma effect, Oncol Rep, 42, 866
  162. Zhang, 2015, Virus-mimetic nanovesicles as a versatile antigen-delivery system, P Natl Acad Sci USA, 112, 6129, 10.1073/pnas.1505799112 · DOI
  163. Wang, 2014, More efficient induction of antitumor T cell immunity by exosomes from CD40l gene-modified lung tumor cells, Mol Med Rep, 9, 125, 10.3892/mmr.2013.1759 · DOI
  164. Phung, 2020, Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses, Acta Biomater, 115, 371, 10.1016/j.actbio.2020.08.008 · DOI
  165. Liu, 2018, Bioinspired artificial nanodecoys for hepatitis B virus, Angew Chem Int Ed Engl, 57, 12499, 10.1002/anie.201807212 · DOI
  166. Fu, 2019, Car exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity, Nat Commun, 10, 4355, 10.1038/s41467-019-12321-3 · DOI
  167. Behzadi, 2017, Macrophage cell-derived exosomes/staphylococcal enterotoxin B against fibrosarcoma tumor, Microb Pathogenesis, 111, 132, 10.1016/j.micpath.2017.08.027 · DOI
  168. Wang, 2019, Exosomes from M1-polarized macrophages enhance paclitaxel antitumor activity by activating macrophages-mediated inflammation, Theranostics, 9, 1714, 10.7150/thno.30716 · DOI · Paper page
  169. Choo, 2018, M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors, ACS Nano, 12, 8977, 10.1021/acsnano.8b02446 · DOI
  170. Fan, 2019, Functionalized DNA enables programming exosomes/vesicles for tumor imaging and therapy, Small, 15, 10.1002/smll.201903761 · DOI
  171. Di Pace, 2020, Characterization of human NK cell-derived exosomes: role of DNAM1 receptor in exosome-mediated cytotoxicity against tumor, Cancers (Basel), 12, 661, 10.3390/cancers12030661 · DOI
  172. Kang, 2021, On-chip biogenesis of circulating NK cell-derived exosomes in non-small cell lung cancer exhibits antitumoral activity, Adv Sci, 8, 10.1002/advs.202003747 · DOI
  173. Peng, 2020, Correlation of plasma exosomal micrornas with the efficacy of immunotherapy in EGFR /ALK wild-type advanced non-small cell lung cancer, J Immunother Cancer, 8, 10.1136/jitc-2019-000376 · DOI
  174. Thery, 2006, Isolation and characterization of exosomes from cell culture supernatants and biological fluids, Curr Protoc Cell Biol, 22
  175. Greening, 2015, A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods, Methods Mol Biol, 1295, 179, 10.1007/978-1-4939-2550-6_15 · DOI
  176. Lobb, 2015, Optimized exosome isolation protocol for cell culture supernatant and human plasma, J Extracell Vesicles, 4, 27031, 10.3402/jev.v4.27031 · DOI
  177. Das, 2019, Exosome as a novel shuttle for delivery of therapeutics across biological barriers, Mol Pharmaceut, 16, 24, 10.1021/acs.molpharmaceut.8b00901 · DOI
  178. Wang, 2021, Towards microfluidic-based exosome isolation and detection for tumor therapy, Nano Today, 37, 10.1016/j.nantod.2020.101066 · DOI
  179. Sun, 2010, A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes, Cancer Res, 18, 1606
  180. Wahlgren, 2012, Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes, Nucleic Acids Res, 40, 130, 10.1093/nar/gks463 · DOI
  181. Kim, 2016, Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells, Nanomed-Nanotechnol, 12, 655, 10.1016/j.nano.2015.10.012 · DOI · Paper page
  182. Sun, 2021, Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis, Biomaterials, 271, 10.1016/j.biomaterials.2021.120761 · DOI
  183. Wang, 2020, Exosomes containing mirnas targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity, J Nanobiotechnol, 18, 153, 10.1186/s12951-020-00711-5 · DOI
  184. Yamashita, 2018, Possibility of exosome-based therapeutics and challenges in production of exosomes eligible for therapeutic application, Biol Pharm Bull, 41, 835, 10.1248/bpb.b18-00133 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zhao, Y., Liu, L., Sun, R., Cui, G., Guo, S., Han, S., Li, Z., Bai, T., & Teng, L.
Venue
Asian Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Published
2022-03
Volume
17
Issue
2
Pages
193-205
ISSN
1818-0876
DOI
10.1016/j.ajps.2021.12.001
PMC
PMC9091780
Cited by
39
References
2
Language
en
Licence
Funders
  • Jilin Province Development and Reform Commission (2019C050-4)
  • National Natural Science Foundation of China (82073784)
  • Jilin University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review